Although new directly acting antiviral drugs (DAAs) have been developed for the treatment of chronic hepatitis C (CHC), these drugs are expensive and therefore pegylated interferon-α- (Peg-INF-α-) 2a or 2b plus a daily weight-based dose of ribavirin could still be the standard of care especially for the treatment of naïve patients with compensated liver functions and/or for those living in developing countries and for whom access to the new drugs is not definite [2–7]. The gene discussed is IFNA17; the disease is cryohydrocytosis.